Several pipeline compounds are in development for once-weekly oral ART and IAS 2025 included several studies on ulonivirine (ULO, MK-8507) and islatravir (ISL).
Ulonivirine is a once-weekly NNRTI that retains activity against drug resistance to early NNRTIs (including K103N, Y181C and G190A) – with a resistance profile similar to doravirine. It is being developed as a partner to one-weekly islatravir and both compounds were put on development hold in 2021 due islatravir-induced reductions in lymphocyte and CD4 counts.
Read the full news story at HIV i-Base.
All HIV i-Base reports from IAS 2025 can be accessed here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.